Panion & Bf Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Panion & Bf Biotech has a total shareholder equity of NT$1.9B and total debt of NT$709.0M, which brings its debt-to-equity ratio to 36.9%. Its total assets and total liabilities are NT$3.2B and NT$1.3B respectively. Panion & Bf Biotech's EBIT is NT$205.7M making its interest coverage ratio 27.1. It has cash and short-term investments of NT$558.4M.
Key information
36.9%
Debt to equity ratio
NT$708.97m
Debt
| Interest coverage ratio | 27.1x |
| Cash | NT$558.37m |
| Equity | NT$1.92b |
| Total liabilities | NT$1.29b |
| Total assets | NT$3.21b |
Recent financial health updates
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?
Aug 13
Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden
Apr 07Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet
Dec 14
Recent updates
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?
Aug 13Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden
Apr 07Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?
Mar 03Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years
Feb 04Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?
Jan 09Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet
Dec 14Financial Position Analysis
Short Term Liabilities: 1760's short term assets (NT$1.5B) exceed its short term liabilities (NT$1.0B).
Long Term Liabilities: 1760's short term assets (NT$1.5B) exceed its long term liabilities (NT$258.4M).
Debt to Equity History and Analysis
Debt Level: 1760's net debt to equity ratio (7.8%) is considered satisfactory.
Reducing Debt: 1760's debt to equity ratio has increased from 0% to 36.9% over the past 5 years.
Debt Coverage: 1760's debt is well covered by operating cash flow (49.5%).
Interest Coverage: 1760's interest payments on its debt are well covered by EBIT (27.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 17:52 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Panion & Bf Biotech Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Jane Jiang | Yuanta Research |